image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

TP receptor

Family: Prostanoid receptors

Contents:
Gene and Protein Information
Previous and Unofficial Names
Database Links
Agonists
Antagonists
Transduction Mechanisms
Tissue Distribution
Expression Datasets
Functional Assays
Physiological Functions
Physiological Consequences of Altering Gene Expression
Phenotypes, Alleles and Disease Models
Biologically Significant Variants
References
Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 343 19p13.3 TBXA2R thromboxane A2 receptor 12
Mouse 7 341 10 C1 Tbxa2r thromboxane A2 receptor 6,34,43
Rat 7 341 7q11 Tbxa2r thromboxane A2 receptor 1
Previous and Unofficial Names
thromboxane
thromboxane A2 / prostaglandin H2
TXA2
TXA2-R
TXR2
Thromboxane receptor
prostanoid TP receptor
thromboxane A2 receptor
Tp receptor
TP
Database Links
ChEMBL Target 246 (Hs), 12480 (Rn)
DrugBank Target 835 (Hs)
Ensembl ENSG00000006638 (Hs), ENSMUSG00000034881 (Mm), ENSRNOG00000020585 (Rn)
Entrez Gene 6915 (Hs), 21390 (Mm), 24816 (Rn)
GeneCards TBXA2R (Hs)
GenitoUrinary Development Molecular Anatomy Project Tbxa2r (Mm)
HomoloGene 825 (Hs)
Human Protein Reference Database 01768 (Hs)
InterPro P21731 (Hs), P30987 (Mm), P34978 (Rn)
KEGG Gene hsa:6915 (Hs), mmu:21390 (Mm), rno:24816 (Rn)
OMIM 188070 (Hs)
PharmGKB Gene PA348 (Hs)
PhosphoSitePlus P21731 (Hs), P30987 (Mm), P34978 (Rn)
Protein Ontology (PRO) PRO:000001676 (Hs)
RefSeq Nucleotide NM_001060 (Hs), NM_009325 (Mm), NM_017054 (Rn)
RefSeq Protein NP_001051 (Hs), NP_033351 (Mm), NP_058750 (Rn)
TreeFam ENSG00000006638 (Hs), ENSMUSG00000034881 (Mm), ENSRNOG00000020585 (Rn)
UniGene Hs. 442530 (Hs)
UniProt P21731 (Hs), P30987 (Mm), P34978 (Rn)
Wikipedia TP receptor
Prostanoid receptors
Search for 3D structures on the PDB
Search by keyword: Prostanoid receptors TP receptor Search by accession number: P34978, P21731, P30987
Natural/Endogenous Ligand(s)
PGD2
PGE2
PGF2α
PGI2
thromboxane A2
Comments: thromboxane A2 is the principal endogenous agonist
Rank order of potency
thromboxane A2 = PGH2 >> PGD2, PGE2, PGF2α, PGI2
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
AGN192093 Hs Agonist - -
I-BOP Hs Agonist 8.94 – 9.32 pKd 27
[125I]BOP Hs Full agonist 8.7 pKd 32
[3H]U46619 Hs Full agonist 7.8 pKd 2
I-BOP Mm Full agonist 9.3 pKi 21
EP 171 Hs Full agonist 8.5 pKi 16
U46609 Hs Full agonist 8.4 pKi 31
STA2 Mm Full agonist 7.9 pKi 21
U46619 Hs Full agonist 7.5 pKi 2
U46619 Mm Full agonist 7.2 pKi 21
CTA2 Hs Full agonist 6.5 pKi 31
M&B 28767 Hs Full agonist 6.5 pKi 2
cloprostenol Hs Full agonist 5.2 pKi 2
iloprost Hs Full agonist 5.2 pKi 2
PGF2α Hs Full agonist 5.1 pKi 2
butaprost (free acid form) Hs Full agonist 4.7 pKi 2
carbacyclin Hs Full agonist 4.7 pKi 2
PGE2 Hs Full agonist 4.5 pKi 2
fluprostenol Hs Full agonist 4.3 pKi 2
STA2 Hs Agonist 6.38 – 7.06 pIC50 4
View species-specific agonist tables
Agonist Comments
References [16,31-32] use human platelet preparations instead of transfected cells.

PGH2 and TXA2 are only rarely used as TP agonists owing to their instability under physiological conditions; U46619 is an appropriate substitute. Partial agonism is common among close analogues of PGH2 and TXA2.

References given alongside the TP receptor agonists I-BOP [27] and STA2 [4] use human platelets as the source of TP receptors for competition radio-ligand binding assays to determine the indicated activity values.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]SQ-29548 Rn Antagonist 9.0 pKd 1
[3H]S-145 Hs Antagonist 8.9 pKd 12
[125I]SAP Hs Antagonist 7.7 – 9.3 pKd 33
[3H]S-145 Mm Antagonist 8.5 pKd 34
[125I]SQ-29548 Hs Antagonist 8.3 pKd 11
[3H]SQ-29548 Hs Antagonist 7.4 – 8.2 pKd 2,52
[125I]PTA-OH Hs Antagonist 7.7 pKd 9
S-145 Hs Antagonist 9.6 pKi 22
ifetroban Hs Antagonist 8.4 – 10.0 pKi 36
S-145 Mm Antagonist 9.2 pKi 21
KW-3635 Hs Antagonist 8.9 pKi 31
GR 32191 Hs Antagonist 8.3 – 9.4 pKi 4,24
SQ-29548 Hs Antagonist 8.1 – 9.1 pKi 2,40,52
ONO 3708 Hs Antagonist 7.4 – 8.9 pKi 18
ramatroban Hs Antagonist 8.0 pKi 44
GR 32191 Mm Antagonist 7.9 pKi 21
SQ-29548 Mm Antagonist 7.9 pKi 21
daltroban Hs Antagonist 7.7 pKi 31
S-5751 Hs Antagonist 7.6 pKi 3
ONO-8711 Hs Antagonist 7.1 pKi 51
AH23848 Hs Antagonist 6.2 pKi 2
View species-specific antagonist tables
Antagonist Comments
References [4,11,18,22,31,33,36,44] use human platelet preparations instead of transfected cells.

A wide range of structurally diverse TP antagonists are known; GR-32191 and SQ-29548 are in common use. Agents combining TP antagonism and IP agonism [5,10,28] and TP antagonism and TX synthase inhibition [48] are known.

Explore drug-target interactions for this set of compounds using iPHACE

Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  20
Tissue Distribution
Uterus.
Species:  Human
Technique:  Immunohistochemistry, immunocytochemistry, Northern blotting, in situ hybridisation, radioligand binding.
References:  39
Brain, thymus, small intestine.
Species:  Human
Technique:  RT-PCR.
References:  29
Placenta > lung.
Species:  Human
Technique:  Northern blotting.
References:  12
Endothelium.
Species:  Human
Technique:  Northern blotting.
References:  37
Platelets.
Species:  Human
Technique:  Radioligand binding.
References:  26
Thymus, lung, kidney, T cell line (EL-4).
Species:  Mouse
Technique:  RNase protection assay.
References:  6
Fetal: thymus, kidney.
Adult: thymus (cortex), spleen (red pulp).
Species:  Mouse
Technique:  in situ hybridisation.
References:  6
CD4+ and CD8+ T cells from the spleen.
Species:  Mouse
Technique:  RT-PCR.
References:  17
Thymus, spleen, lung.
Species:  Mouse
Technique:  Northern blotting.
References:  34
Platelets.
Species:  Rat
Technique:  Radioligand binding.
References:  26
Kidney: glomeruli, arterial walls, luminal membranes of thick ascending limbs of Henle's loop, luminal and basolateral membranes of either distal convoluted tubules or connecting tubules, the basolateral membranes of collecting tubules.
Species:  Rat
Technique:  Western blotting.
References:  41
Expression Datasets

Click here to show/hide data

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of Ca2+ levels in HEK 293 cells transfected with the human TP receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Increase in Ca2+ concentration.
References:  20,50
Measurement of Ca2+ in human platelets endogenously expressing the TP receptor.
Species:  Human
Tissue:  Platelets.
Response measured:  Increase in Ca2+ concentration.
References:  20,50
Measurement of Ca2+ levels, using a Ca2+-activated Cl- channel, in Xenopus oocytes transfected with the human TP receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Increase in Ca2+ concentration.
References:  12
Measurement of ERK and JNK activity in HEK 293 cells transfected with the human TP receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Activation of ERK signalling cascade.
References:  30
Measurement of ERK and JNK activity in human uterine ULTR cell line endogenously expressing the TP receptor.
Species:  Human
Tissue:  Uterine ULTR cell line.
Response measured:  Activation of ERK signalling cascade.
References:  30
Measurement of Ca2+ levels in COS-7 cells transfected with the rat TP receptor.
Species:  Rat
Tissue:  COS-7 cells.
Response measured:  Increase in free Ca2+ concentration.
References:  1
Measurement of Ca2+ levels in Xenopus oocytes transfected with the rat TP receptor using electrophysiology.
Species:  Rat
Tissue:  Xenopus oocytes.
Response measured:  Increase in Ca2+ concentration.
References:  1
Physiological Functions
Contraction of pulmonary venous smooth muscle.
Species:  Human
Tissue:  Pulmonary venous preparations.
References:  35,49
Contraction of pulmonary arterial smooth muscle.
Species:  Human
Tissue:  Pulmonary vascular preparations.
References:  35
Contraction of bronchial smooth muscle.
Species:  Human
Tissue:  Bronchial smooth muscle preparations.
References:  7
Bronchoconstriction.
Species:  Human
Tissue:  In vivo.
References:  15
Vasoconstriction.
Species:  Rat
Tissue:  In vivo.
References:  47
Platelet aggregation.
Species:  Human
Tissue:  In vivo.
References:  8
Platelet aggregation.
Species:  Human
Tissue:  Platelets.
References:  25
Mediation of cellular immune responses and inflammatory tissue injury.
Species:  Mouse
Tissue:  In vivo.
References:  46
Physiological Consequences of Altering Gene Expression
TP receptor knockout mice exhibit an increase in bleeding time and impaired platelet aggregation in response to TP receptor agonists.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  45
TP receptor knockout mice enhibit altered renal vascular tone.
Species:  Rat
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  38
Spleen cells from TP receptor knockout mice exhibit reduced cellular immune responsiveness and TP receptor knockout mice exhibit reduced immune-mediated tissue injury following cardiac transplant rejection in vivo.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  46
TP receptor knockout mice exhibit enhanced immune responses and the development of lymphadenopathy.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  17
TP receptor knockout mice exhibit inhibition of cytokine-induced increase in beating rate, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  42
TP knockout mice display delayed atherogenesis and impaired inflammatory tachycarcia.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  23,42
Phenotypes, Alleles and Disease Models Mouse data from MGI

Click here to show/hide data

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Tbxa2rtm1Cof Tbxa2rtm1Cof/Tbxa2rtm1Cof
C.129P2(B6)-Tbxa2r		 MGI:98496  MP:0000249 abnormal blood vessel physiology PMID: 11964481 
Tbxa2rtm1Cof Tbxa2rtm1Cof/Tbxa2rtm1Cof
either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * 129S/SvEv)		 MGI:98496  MP:0001544 abnormal cardiovascular system physiology PMID: 9835625 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0002351 abnormal cervical lymph node morphology PMID: 12778172 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0002723 abnormal immune serum protein physiology PMID: 12778172 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0002722 abnormal immune system organ morphology PMID: 12778172 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0001790 abnormal immune system physiology PMID: 12778172 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0002339 abnormal lymph node morphology PMID: 12778172 
Tbxa2rtm1Cof Tbxa2rtm1Cof/Tbxa2rtm1Cof
either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * 129S/SvEv)		 MGI:98496  MP:0009548 abnormal platelet aggregation PMID: 9835625 
Tbxa2rtm1Cof Tbxa2rtm1Cof/Tbxa2rtm1Cof
C.129P2(B6)-Tbxa2r		 MGI:98496  MP:0005464 abnormal platelet physiology PMID: 11964481 
Tbxa2rtm1Cof Tbxa2rtm1Cof/Tbxa2rtm1Cof
C.129P2(B6)-Tbxa2r		 MGI:98496  MP:0009818 abnormal thromboxane level PMID: 11964481 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0002531 abnormal type I hypersensitivity reaction PMID: 12778172 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0000702 enlarged lymph nodes PMID: 12778172 
Tbxa2rtm1Sna Tbxa2rtm1Sna/Tbxa2rtm1Sna
either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6)		 MGI:98496  MP:0000691 enlarged spleen PMID: 12778172 
Tbxa2rtm1Cof Tbxa2rtm1Cof/Tbxa2rtm1Cof
either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * 129S/SvEv)		 MGI:98496  MP:0005606 increased bleeding time PMID: 9835625 
Biologically Significant Variants
Two splice variants of the TP receptor have been found in humans, TPα and TPβ, containing an identical 328 amino acid sequence but differing in their 15 amino acid and 79 amino acid, respectively, C-terminal regions. They have identical ligand and G protein binding properties, similarly regulate PLC, but they are differentially expressed throughout the body and oppositely regulate adeylate cyclase activity.
Type:  Splice variants.
Species:  Human
References:  14,19-20,37,50
An Arg60 -> Leu substitution has been identified in patients suffering from a dominantly inherited bleeding disorder. This mutant receptor displays normal ligand binding but defective signal transduction when expressed in CHO cells.
Type:  Single nucleotide polymorphism.
Species:  Human
References:  13

REFERENCES

Show »

1. Abe, T., Takeuchi, K., Takahashi, N., Tsutsumi, E., Taniyama, Y. and Abe, K. (1995) Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest, 96: 657-664. [PMID:7635958]

2. Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N. M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N. and Metters, K. M. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogues. Biochim. Biophys. Acta., 1483: 285-293. [PMID:10634944]

3. Arimura, A., Yasui, K., Kishino, J., Asanuma, F., Hasegawa, H., Kakudo, S., Ohtani, M. and Arita, H. (2001) Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther, 298: 411-419. [PMID:11454901]

4. Armstrong, R. A., Humphrey, P. P. and Lumley, P. (1993) Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets. Br J Pharmacol, 110: 539-547. [PMID:8242228]

5. Armstrong, R. A., Jones, R. L., MacDermot, J. and Wilson, N. H. (1986) Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol, 87: 543-551. [PMID:3026540]

6. Båtshake, B., Nilsson, C. and Sundelin, J. (1999) Structure and expression of the murine thromboxane A2 receptor gene. Biochem Biophys Res Commun, 256: 391-397. [PMID:10079195]

7. Coleman, R. A. and Sheldrick, R. L. (1989) Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br J Pharmacol, 96: 688-692. [PMID:2720298]

8. Gresele, P., Arnout, J., Deckmyn, H., Huybrechts, E., Pieters, G. and Vermylen, J. (1987) Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest, 80: 1435-1445. [PMID:2960694]

9. Halushka, P. V., Kochel, P. J. and Mais, D. E. (1987) Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Br J Pharmacol, 91: 223-227. [PMID:3594077]

10. Hamanaka, N., Takahashi, K., Nagao, Y., Torisu, K., Tokumoto, H. and Kondo, K. (1995) Molecular design of novel PGI2 agonists without PG skeleton. Biorg Med Chem Lett, 5: 1065-1070.

11. Hedberg, A., Hall, S. E., Ogletree, M. L., Harris, D. N. and Liu, E. C.-K. (1988) Characterisation of [5,6-3H] SQ29,548 as a high affinity radioligand binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J. Pharmacol. Exp. Ther., 245: 786-792. [PMID:2968449]

12. Hirata, M., Hayishi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S. and Narumiya, S. (1991) Cloning and expression of human thromboxane A2 receptor. Nature, 349: 617-620. [PMID:1825698]

13. Hirata, T., Kakizuka, A., Ushikubi, F., Fuse, I., Okuma, M. and Narumiya, S. (1994) Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest, 94: 1662-1667. [PMID:7929844]

14. Hirata, T., Ushikubi, F., Kakizuka, A., Okuma, M. and Narumiya, S. (1996) Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60to Leu mutation. J. Clin. Invest., 97: 949-956. [PMID:8613548]

15. Johnston, S. L., Freezer, N. J., Ritter, W., O'Toole, S. and Howarth, P. H. (1995) Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur Respir J, 8: 411-415. [PMID:7789486]

16. Jones, R. L., Wilson, N. H. and Lawrence, R. A. (1989) EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade. Br J Pharmacol, 96: 875-887. [PMID:2743082]

17. Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D., Yoshida, N., Katagiri, K., Kinashi, T., Tanaka, T., Miyasaka, M., Nagai, H., Ushikubi, F. and Narumiya, S. (2003) Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol, 4: 694-701. [PMID:12778172]

18. Kattelman, E. J., Venton, D. L. and Le Breton, G. C. (1986) Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res, 41: 471-481. [PMID:3008368]

19. Kinsella, B. T. (2001) Thromboxane A2 signalling in humans: a 'Tail' of two receptors. Biochem Soc Trans, 29: 641-654. [PMID:11709048]

20. Kinsella, B. T., O'Mahony, D. J. and FitzGerald, G. A. (1997) The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther, 281: 957-964. [PMID:9152406]

21. Kiriyama, M., Ushikubi, F., Kobayashi, T., Hirata, M., Sugimoto, Y. and Narumiya, S. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol., 122: 217-224. [PMID:9313928]

22. Kishino, J., Hanasaki, K., Nagasaki, T. and Arita, H. (1991) Kinetic studies on stereospecific recognition by the thromboxane A2/prostaglandin H2 receptor of the antagonist, S-145. Br. J. Pharmacol., 103: 1883-1888. [PMID:1833018]

23. Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., Katagiri, H., Majima, M., Yokode, M., Kita, T. and Narumiya, S. (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest, 114: 784-794. [PMID:15372102]

24. Lumley, P., White, B. P. and Humphrey, P. P. (1989) GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol, 97: 783-794. [PMID:2527074]

25. Mais, D. E., DeHoll, D., Sightler, H. and Halushka, P. V. (1988) Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels. Eur. J. Pharmacol., 148: 309-315. [PMID:2968271]

26. Masuda, A., Mais, D. E., Oatis, J. E. and Halushka, P. V. (1991) Platelet and vascular thromboxane A2/prostaglandin H2 receptors: Evidence for different subclasses in the rat. Biochem. Pharmacol., 42: 537-544. [PMID:1830482]

27. Mayeux, PR; Morinelli, TA; Williams, TC; Hazard, ES; Mais, DE; Oatis, JE; Baron, DA; Halushka, PV. (1991) Differential effect of pH on thromboxane A2/prostaglandin H2 receptor agonist and antagonist binding in human platelets. J. Biol. Chem., 266 (21): 13752-8. [PMID:1830308]

28. Meanwell, N. A., Romine, J. L., Rosenfeld, M. J., Martin, S. W., Trehan, A. K., Wright, J. J., Malley, M. F., Gougoutas, J. Z., Brassard, C. L. and Buchanan, J. O. (1993) Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid. J Med Chem, 36: 3884-3903. [PMID:7504734]

29. Miggin, S. M. and Kinsella, B. T. (1998) Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta, 1425: 543-559. [PMID:9838218]

30. Miggin, S. M. and Kinsella, B. T. (2001) Thromboxane A(2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. Biochim Biophys Acta, 1539: 147-162. [PMID:11389977]

31. Miki, I., Kishibayashi, N., Nonaka, H., Ohshima, E., Takami, H., Obase, H. and Ishii, A. (1992) Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol, 59: 357-364. [PMID:1434130]

32. Morinelli, T. A., Oatis, J. E., Okwu, A. K., Mais, D. E., Mayeux, P. R., Masuda, A., Knapp, D. R. and Halushka, P. V. (1989) Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther, 251: 557-562. [PMID:2530338]

33. Naka, M., Mais, D. E., Morinelli, T. A., Hamanaka, N., Oatis, J. E. and Halushka, P. V. (1992) 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther, 262: 632-637. [PMID:1386885]

34. Namba, T., Sugimoto, Y., Hirata, M., Hayashi, Y., Honda, A., Watabe, A., Negishi, M., Ichikawa, A. and Narumiya, S. (1992) Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem. Biophys. Res. Commun., 184: 1197-1203. [PMID:1375456]

35. Norel, X., de Montpreville, V. and Brink, C. (2004) Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat, 74: 101-112. [PMID:15560119]

36. Ogletree, M. L., Harris, D. N., Schumacher, W. A., Webb, M. L. and Misra, R. N. (1993) Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J. Pharmacol. Exp. Ther., 264: 570-578. [PMID:8437108]

37. Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C. and Ware, J. A. (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane receptor. J. Biol. Chem., 269: 19256-19261. [PMID:8034687]

38. Schnermann, J., Traynor, T., Pohl, H., Thomas, D. W., Coffman, T. M. and Briggs, J. P. (2000) Vasoconstrictor responses in thromboxane receptor knockout mice: tubuloglomerular feedback and ureteral obstruction. Acta Physiol Scand, 168: 201-207. [PMID:10691801]

39. Swanson, M. L., Lei, Z. M., Swanson, P. H., Rao, C. V., Narumiya, S. and Hirata, M. (1992) The expression of thromboxane A2 synthase and thromboxane A2 receptor gene in human uterus. Biol Reprod, 47: 105-117. [PMID:1386258]

40. Swayne, GT; Maguire, J; Dolan, J; Raval, P; Dane, G; Greener, M; Owen, DA. (1988) Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists. Eur. J. Pharmacol., 152 (3): 311-9. [PMID:2975605]

41. Takahashi, N., Takeuchi, K., Abe, T., Sugawara, A. and Abe, K. (1996) Immunolocalization of rat thromboxane receptor in the kidney. Endocrinology, 137: 5170-5173. [PMID:8895394]

42. Takayama, K., Yuhki, K., Ono, K., Fujino, T., Hara, A., Yamada, T., Kuriyama, S., Karibe, H., Okada, Y., Takahata, O., Taniguchi, T., Iijima, T., Iwasaki, H., Narumiya, S. and Ushikubi, F. (2005) Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med, 11: 562-566. [PMID:15834430]

43. Taketo, M., Rochelle, J. M., Sugimoto, Y., Namba, T., Honda, A., Negishi, M., Ichikawa, A., Narumiya, S. and Seldin, M. F. (1994) Mapping of the genes encoding mouse thromboxane A2 receptor and prostaglandin E receptor subtypes EP2 and EP3. Genomics, 19: 585-588. [PMID:7910583]

44. Theis, J. G., Dellweg, H., Perzborn, E. and Gross, R. (1992) Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes. Biochem Pharmacol, 44: 495-503. [PMID:1387312]

45. Thomas, D. W., Mannon, R. B., Mannon, P. J., Latour, A., Oliver, J. A., Hoffman, M., Smithies, O., Koller, B. H. and Coffman, T. M. (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest., 102: 1994-2001. [PMID:9835625]

46. Thomas, D. W., Rocha, P. N., Nataraj, C., Robinson, L. A., Spurney, R. F., Koller, B. H. and Coffman, T. M. (2003) Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J Immunol, 171: 6389-6395. [PMID:14662837]

47. Valentin, J. P., Bessac, A. M., Maffre, M. and John, G. W. (1996) Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat. Eur J Pharmacol, 317: 335-342. [PMID:8997619]

48. Vermylen, J. and Deckmyn, H. (1992) Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drugs Ther, 6: 29-33. [PMID:1533533]

49. Walch, L., de Montpreville, V., Brink, C. and Norel, X. (2001) Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol, 134: 1671-1678. [PMID:11739243]

50. Walsh, M. T. and Kinsella, B. T. (2000) Regulation of the human prostanoid TPalpha and TPbeta receptor isoforms mediated through activation of the EP(1) and IP receptors. Br J Pharmacol, 131: 601-609. [PMID:11015313]

51. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Ushikubi, F., Narumiya, S., Sugimura, T. and Wakabayashi, K. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res, 59: 5093-5096. [PMID:10537280]

52. Wilson, R. J., Giblin, G. M., Roomans, S., Rhodes, S. A., Cartwright, K. A., Shield, V. J., Brown, J., Wise, A., Chowdhury, J., Pritchard, S., Coote, J., Noel, L. S., Kenakin, T., Burns-Kurtis, C. L., Morrison, V., Gray, D. W. and Giles, H. (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol, 148: 326-339. [PMID:16604093]

To cite this database page, please use the following:

Mark Abramovitz, Richard M. Breyer, Robert A. Coleman, Rebecca Hills, Robert L. Jones, Shuh Narumiya, David F. Woodward.
Prostanoid receptors: TP receptor. Last modified on 13/03/2013. Accessed on 24/05/2013. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=346.


Contact us | Print | Back to top | Help